Anticorps Anti - SMAD6 (C - terminal) produit en lapin, environ 1,0 mg/ mL, anticorps isolé affinité

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

SMAD family member 6 (SMAD6) induces endocytosis and negatively regulates apoptosis by inhibiting transforming growth factor-β (TGF-β) signaling pathway. In addition, it also indirectly regulates stemness by inhibiting erythropoiesis in cord blood hematopoietic stem cells (HSCs). Mutation in the gene leads to congenital cardiovascular malformation (CVM). Overexpression or genetic variation of SMAD6 is associated with the development of ovarian cancer.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

SMAD family member 6 (SMAD6) is encoded by the gene mapped to human chromosome 15q22.31. The encoded protein is localized in both nuclei and cytoplasm and is expressed in variety of human tissues, including ovary. SMAD6 consists of MAD homology 2 (MH2) domain, involved in protein-protein interaction.

Immunogen

peptide corresponding to the C-terminal region of human SMAD6, conjugated to KLH. The corresponding sequence is identical in rat, mouse and bovine.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.